These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6418264)

  • 1. Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormone.
    Waxman JH; Wass JA; Hendry WF; Whitfield HN; Bary P; Besser GM; Malpas JS; Oliver RT
    Br J Urol; 1983 Dec; 55(6):737-42. PubMed ID: 6418264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
    Waxman JH; Hendry WF; Whitfield HN; Oliver RT
    Prog Clin Biol Res; 1985; 185A():271-7. PubMed ID: 3929266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
    Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
    Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The first clinical use of depot buserelin for advanced prostatic carcinoma.
    Waxman JH; Sandow J; Man A; Barnett MJ; Hendry WF; Besser GM; Oliver RT; Magill PJ
    Cancer Chemother Pharmacol; 1986; 18(2):174-5. PubMed ID: 3098445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application].
    Niijima T; Kishimoto T; Shimazaki J; Yoshida O; Isurugi K
    Hinyokika Kiyo; 1988 Jul; 34(7):1309-19. PubMed ID: 3140622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
    Wenderoth UK; Jacobi GH
    Ann Urol (Paris); 1986; 20(2):95-7. PubMed ID: 3087269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
    Schroeder FH; Lock TM; Chadha DR; Debruyne FM; Karthaus HF; de Jong FH; Klijn JG; Matroos AW; de Voogt HJ
    J Urol; 1987 May; 137(5):912-8. PubMed ID: 2952810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer.
    Waxman JH; Sandow J; Abel P; Farah N; O'Donoghue EP; Fleming J; Cox J; Sikora K; Williams G
    Acta Endocrinol (Copenh); 1989 Mar; 120(3):315-8. PubMed ID: 2494825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin.
    Falkson CI; Falkson G; Falkson HC
    Ann Oncol; 1991 Apr; 2(4):303-4. PubMed ID: 1907843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
    Debruyne FM; Denis L; Lunglmayer G; Mahler C; Newling DW; Richards B; Robinson MR; Smith PH; Weil EH; Whelan P
    J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy of subcutaneous and nasal spray buserelin treatment in suppression of testicular steroidogenesis in men with prostate cancer.
    Rajfer J; Handelsman DJ; Crum A; Steiner B; Peterson M; Swerdloff RS
    Fertil Steril; 1986 Jul; 46(1):104-10. PubMed ID: 3087785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
    N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment.
    Wenderoth UK; Jacobi GH
    Prog Clin Biol Res; 1985; 185A():297-305. PubMed ID: 3162176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of prostatic cancer with LH-RH analogues.
    Borgmann V; Nagel R; Al-Abadi H; Schmidt-Gollwitzer M
    Prostate; 1983; 4(6):553-68. PubMed ID: 6415628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal buserelin in the treatment of advanced prostatic cancer: a phase II trial.
    Falkson G; Vorobiof DA
    J Clin Oncol; 1987 Sep; 5(9):1419-23. PubMed ID: 3114438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of buserelin in advanced prostate cancer and comparison with historical controls.
    Soloway MS
    Am J Clin Oncol; 1988; 11 Suppl 1():S29-32. PubMed ID: 3133944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V; al-Abadi H; Nagel R
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced carcinoma of the prostate with a depot luteinizing hormone-releasing hormone analogue (ICI-118630).
    Van Cangh PJ; Opsomer RJ
    J Urol; 1987 Jan; 137(1):61-4. PubMed ID: 2948026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B; Varenhorst E; Petas A; Sandow J
    Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.